 Connection
William Robinson to Clinical Trials as Topic
This is a "connection" page, showing publications William Robinson has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.045 |
|
|
|
-
Hintzsche JD, Yoo M, Kim J, Amato CM, Robinson WA, Tan AC. IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. BMC Med Genomics. 2018 04 20; 11(Suppl 2):26.
Score: 0.025
-
Frontiera M, Murray JL, Lamki L, Thomas J, Satterlee W, Schmelter R, Rosenblum MG, Khazaeli MB, Unger MW, Robinson WA, et al. Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma. Clin Nucl Med. 1989 May; 14(5):357-66.
Score: 0.013
-
Kirkwood JM, Ernstoff MS, Giuliano A, Gams R, Robinson WA, Costanzi J, Pouillart P, Speyer J, Grimm M, Spiegel R. Interferon alpha-2a and dacarbazine in melanoma. J Natl Cancer Inst. 1990 Jun 20; 82(12):1062-3.
Score: 0.004
-
Steele MT, Sainsbury CR, Robinson WA, Salomone JA, Elenbaas RM. Prophylactic penicillin for intraoral wounds. Ann Emerg Med. 1989 Aug; 18(8):847-52.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|